Protagonist Therapeutics, Inc Operating Lease, Liability, Noncurrent
Protagonist Therapeutics, Inc (PTGX) had Operating Lease, Liability, Noncurrent of $6.82 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:OperatingLeaseLiabilityNoncurrent · last filed 2026-08-05
- 2026-06-30: Operating Lease, Liability, Noncurrent $6.82M.
- 2026-03-31: Operating Lease, Liability, Noncurrent $7.44M.
- 2025-12-31: Operating Lease, Liability, Noncurrent $8.04M.
- 2025-09-30: Operating Lease, Liability, Noncurrent $8.52M.
| Period end | Operating Lease, Liability, Noncurrent |
|---|---|
| 2026-06-30 | $6.82M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $7.44M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $8.04M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $8.52M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $9.11M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $9.79M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $10.36M 10-K · filed 2026-02-25 |
| 2024-09-30 | $10.86M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $10.97M 10-Q · filed 2024-08-06 |
| 2023-03-31 | $462.00K 10-Q · filed 2023-05-04 |
| 2022-12-31 | $1.14M 10-K · filed 2024-02-27 |
| 2022-09-30 | $1.80M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $2.45M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $3.06M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $3.66M 10-K · filed 2023-03-15 |
| 2021-09-30 | $4.24M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $3.69M 10-Q · filed 2021-08-04 |
| 2021-03-31 | $4.10M 10-Q · filed 2021-05-04 |
| 2020-12-31 | $4.50M 10-K · filed 2022-02-28 |
| 2020-09-30 | $4.88M 10-Q · filed 2020-11-04 |
| 2020-06-30 | $5.26M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $5.62M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $5.96M 10-K · filed 2021-03-10 |
| 2019-09-30 | $6.29M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $6.62M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $6.92M 10-Q · filed 2019-05-08 |
| 2019-01-01 | $7.22M 10-Q · filed 2019-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |